奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的临床疗效及安全性研究  

Clinical Efficacy and Safety Study of Octreotide Combined with Thrombin in Liver Cirrhosis Combined with Upper Gastrointestinal Bleeding

作　　者：朱海波 杨位轩 刘成 刘杰 Zhu Haibo;Yang Weixuan;Liu Cheng(Department of Gastroenterology,Huai’an Hospital Affiliated to Yangzhou University,Huai’an,Jiangsu,223300,China)

机构地区：[1]扬州大学附属淮安医院(淮安市第五人民医院)消化内科,江苏淮安223300

出　　处：《黑龙江医学》2025年第9期1057-1059,1063,共4页Heilongjiang Medical Journal

基　　金：江苏省老年健康科研项目(LKM2022030)。

摘　　要：目的:分析奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的疗效及安全性。方法:选取2022年3月—2024年3月淮安市第五人民医院收治的78例肝硬化合并上消化道出血患者作为研究对象,采用随机数表法将其分为对照组和研究组,每组各39例。两组患者均进行常规治疗,对照组结合凝血酶,研究组在对照组的基础上使用奥曲肽。对比两组患者临床疗效、止血情况、肝功能、不良反应、生活质量。结果:研究组患者临床疗效优于对照组,差异有统计学意义(χ^(2)=3.923,P<0.05);研究组患者止血时间短于对照组,输血量均低于对照组,差异均有统计学意义(t=9.546、25.185,P<0.05);治疗后,研究组患者丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBiL)水平均低于对照组,差异均有统计学意义(t=13.336、12.571、17.796,P<0.05);研究组患者不良反应发生率低于对照组,差异有统计学意义(χ^(2)=5.014,P<0.05);治疗后,研究组患者生活质量简表(WHOQOL-100)评分均高于对照组,差异均有统计学意义(t=4.078、2.722、5.018、3.675、2.088,P<0.05)。结论:奥曲肽联合凝血酶治疗肝硬化合并上消化道出血临床疗效较高,能够缩短止血时间,提高患者肝功能及生活质量,且安全性较高。Objective:To analyze the effect of octreotide combined with thrombin in liver cirrhosis combined with upper gastrointestinal bleeding.Methods:78 patients with cirrhosis and upper gastrointestinal bleeding from March 2022 to March 2024 were selected,and they were divided into control group and strudy group,with 39 cases in each group.Both groups were treated routinely.The control group combined with thrombin,and the study received octreotide.Clinical efficacy,hemostasis,liver function,adverse effects and quality of life were compared between the two groups.Results:The clinical effect of the study group was better than that of the control group,and the difference was statistically significant(χ^(2)=3.923,P<0.05).The hemostasis time of the study group was shorter than that of the control group,and the blood transfusion volume was lower,with statistically significant difference(t=9.546,25.185;P<0.05).After treatment,ALT,AST and TBiL levels in the study group were lower than those in the control group,with statistically significant difference(t=13.336,12.571,17.796;P<0.05).The incidence of adverse reactions in the study group was significantly lower than that the control group(χ^(2)=5.014,P<0.05).After treatment,the WHOQOL-100 score of the study group was higher than that of the control group,with statistically significant difference(t=4.078,2.722,5.018,3.675,2.088;P<0.05).Conclusion:Octreotide combined with thrombin in cirrhosis combined with upper gastrointestinal bleeding has high clinical efficacy.It can shorten the hemostasis time,promote the liver function,and improve the quality of life.And it is high safety.

关 键 词：奥曲肽 凝血酶 肝硬化 上消化道出血 止血时间 

分 类 号：R657.31[医药卫生—外科学]